David Pilecky
Overview
Explore the profile of David Pilecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banfi-Bacsardi F, Kazay A, Gergely T, Forrai Z, Fuzesi T, Hanuska L, et al.
J Clin Med
. 2025 Jan;
14(1.
PMID: 39797222
: In heart failure (HF) with reduced ejection fraction (HFrEF), the early diagnosis and proper treatment of comorbidities (CMs) are of fundamental relevance. Our aim was to assess the prevalence...
2.
Banfi-Bacsardi F, Boldizsar E, Gergely G, Forrai Z, Kazay A, Fuzesi T, et al.
Orv Hetil
. 2024 Sep;
165(37):1461-1471.
PMID: 39277850
No abstract available.
3.
Gergely G, Banfi-Bacsardi F, Komaromi A, Pilecky D, Boldizsar E, Flegler D, et al.
Orv Hetil
. 2024 Aug;
165(31):1197-1205.
PMID: 39146024
No abstract available.
4.
Erath J, Vigh N, Muk B, Israel C, Keck S, Pilecky D, et al.
J Cardiovasc Dev Dis
. 2024 Jun;
11(6).
PMID: 38921673
(1) Introduction: Digitalis use in patients with severe heart failure is controversial. We assessed the effects of digitalis therapy on mortality in a large, observational study in recipients of cardiac...
5.
Muk B, Pilecky D, Banfi-Bacsardi F, Fuzesi T, Gergely G, Komaromi A, et al.
Orv Hetil
. 2024 May;
165(18):698-710.
PMID: 38709594
No abstract available.
6.
Banfi-Bacsardi F, Pilecky D, Vamos M, Majoros Z, Torok G, Borsanyi T, et al.
Clin Cardiol
. 2024 Feb;
47(2):e24244.
PMID: 38402552
Background: Kidney dysfunction (KD) is a main limiting factor of applying guideline-directed medical therapy (GDMT) and reaching the recommended target doses (TD) in heart failure (HF) with reduced ejection fraction...
7.
Muk B, Banfi-Bacsardi F, Vamos M, Pilecky D, Majoros Z, Torok G, et al.
Diagnostics (Basel)
. 2024 Jan;
14(2).
PMID: 38248008
(1) Background: Besides the use of guideline-directed medical therapy (GDMT), multidisciplinary heart failure (HF) outpatient care (HFOC) is of strategic importance in HFrEF. (2) Methods: Data from 257 hospitalised HFrEF...
8.
Simon A, Pilecky D, Kiss L, Vamos M
J Cardiovasc Dev Dis
. 2023 Oct;
10(10).
PMID: 37887872
Cardiac resynchronization therapy (CRT) is a cornerstone therapeutic opportunity for selected patients with heart failure. For optimal patient selection, no other method has been proven to be more effective than...
9.
Banfi-Bacsardi F, Vamos M, Majoros Z, Torok G, Pilecky D, Duray G, et al.
Orv Hetil
. 2023 Sep;
164(35):1387-1396.
PMID: 37660348
Introduction: Renal dysfunction is a main limiting factor of applying and up-titrating guideline-directed medical therapy (GDMT) among patients with heart failure with reduced ejection fraction (HFrEF). Objective: Our retrospective monocentric...
10.
Pilecky D, Fischer R, Elsner D
Eur Heart J Case Rep
. 2023 Apr;
7(4):ytad144.
PMID: 37063380
No abstract available.